Home › Non-Small Cell Lung Cancer › New York › Rochester
Non-Small Cell Lung Cancer clinical trials in Rochester, NY
13 studies for Non-Small Cell Lung Cancer are looking for participants at sites in and around Rochester (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RecruitingPhase 3
- Rochester General Hospital, Rochester
- University of Rochester, Rochester
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
RecruitingPhase 3
- Wilmot Cancer Institute ( Site 0141), Rochester
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RecruitingPhase 3
- Research Site, Rochester
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
RecruitingPhase 3
- University of Rochester Medical Center, Rochester
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RecruitingPhase 2/3
- Rochester General Hospital Infectious Disease, Rochester
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
RecruitingPhase 3
- University of Rochester, Rochester
Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy
RecruitingHealthy volunteers welcome
- University of Rochester, Rochester
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
RecruitingPhase 3
- University of Rochester Medical Center, Rochester
Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
RecruitingPhase 1
- University of Rochester, Rochester
- University of Rochester, Rochester
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RecruitingPhase 2
- University of Rochester, Rochester
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2/3
- University of Rochester, Rochester
- Wilmot Cancer Institute at Webster, Webster · 10 mi away
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2
- University of Rochester, Rochester
Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax
RecruitingPhase 2
- University of Rochester, Rochester
Non-Small Cell Lung Cancer trials in other cities
- Houston, TX145 studies
- New York City, NY121 studies
- Arlington, VA104 studies
- Nashville, TN97 studies
- Boston, MA90 studies
- Los Angeles, CA87 studies
- St. Louis, MO73 studies
- Chicago, IL61 studies
- Baltimore, MD60 studies
- San Antonio, TX59 studies
- Columbus, OH57 studies
- Washington, DC55 studies
Other studies in Rochester
- Acute Myeloid Leukemia16 studies
- Lung Cancer15 studies
- Breast Cancer15 studies
- Cancer (all types)14 studies
- Obesity14 studies
- Overweight13 studies
- Prostate Cancer10 studies
- Metastatic Cancer8 studies
- Multiple Myeloma8 studies
- Bladder Cancer7 studies
- Myotonic Dystrophy7 studies
- Pancreatic Cancer7 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.